ATOS

Atossa Genetics Inc (ATOS) | Rumor.io

Atossa Genetics

ATOS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,642

Bullish sentiment (50-day avg)69%

Price to earnings ratio-0.49

Market capitalization19.6M

Earnings per share-4.34

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-34.8M

Social

What share of all stock conversation is about ATOS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

Aug 17

Atossa Therapeutics, Inc. ($ATOS) has a market capitalization of $25M, which is significantly lower than its peers, potentially leading to a 38x increase in value.
The company is expected to release trial data by the end of August or early September, which could be a catalyst for the stock to rise.
There are concerns that Atossa may struggle to fund its phase 2 study without a significant injection of capital, which could lead to a reverse split or delisting.

Generated by AI

Sentiment

Of the messages about ATOS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% new	12.5% -87.5	70.37% +2.19	67.13% -4.66
Bearish	50% -50	87.5% new	29.63% -2.19	32.87% +4.66

Bullish· Feb 3

The stock has been beaten down significantly, offering a potential buying opportunity with a possible recovery.
The company's product has been undervalued, and a shift in management's attitude could lead to increased confidence and a boost in the stock price.
The stock is showing signs of a potential bottom, with a possible breakout and increased momentum following a recent surge in volume.

Bearish· Jun 24

The company's management has diluted stock to pay themselves, causing losses for shareholders.
The company is still in the early stages of development and lacks meaningful data, making it unlikely to receive FDA approval soon.
The company's reverse split may lead to delisting from the NYSE due to a rule against multiple splits within a year, and a move to the OTC market could be disastrous for shareholders.

Generated by AI

Topics

Of the messages about ATOS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	56.67%	29.3%
Analysts	—	—	0%	27.69%
Technical Analysis	—	—	0%	33.49%
Controversies	—	—	43.33%	2.44%
Earnings	—	—	0%	0.41%
Macro	—	—	0%	6.66%

Announcements· Jul 29

Atossa Therapeutics ($ATOS) received positive written feedback from the FDA regarding its proposed dose optimization trial of (Z)-endoxifen for ER+/HER2- metastatic breast cancer.
The FDA affirmed key elements of the company's clinical development plan, including the dose-optimization strategy, nonclinical data, combination therapy approach, and cardiac safety, without requiring a pre-IND meeting.
Atossa Therapeutics is advancing toward IND submission for its (Z)-Endoxifen clinical program in ER+/HER2- metastatic breast cancer, with a target submission date in Q4 2025.

Controversies· Feb 15

ATOS is mentioned in a post that criticizes the FDA, potentially implying a negative impact on the company.
The post implies that the FDA's actions or decisions may be seen as unpredictable or incompetent.
The tone of the post is negative and sarcastic, potentially affecting investor sentiment.

Technical Analysis· Dec 11

The author sees up to 50% upside potential for $ATOS, with a first wall at $0.95 and a bullish momentum as long as it remains above $0.80.
Technical levels of interest for $ATOS include $1.05, $2.31, and $0.90, with potential resistance at $1.05 and a recent high/squeeze zone at $2.31.
The author notes that $ATOS has been in an uptrend since December 1, with a bottom at $0.70, and suggests setting limit buys in the mid-to-late $0.80 range for swing trades.

Generated by AI

Community

Of the messages about ATOS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	88.71%	87.86%
Newcomers	0%	0%	11.29%	12.14%

Regulars· Aug 17

The potential catalysts for the stock's price increase include the Evangeline trial data by the end of August or early September, followed by the I-SPY2 data and Karisma durability data by the end of September.
The stock's market capitalization is still under $26 million, which is considered relatively low compared to similar biotech companies in phase 3 with less drug candidates, potentially leading to a significant price increase.
The company's prospects for FDA approval and continued funding are uncertain, with some users expressing skepticism about the stock's potential for significant growth, while others are optimistic about the company's prospects despite the lack of news.

Newcomers· Jul 29

$ATOS stock has seen a 22% increase premarket, with analysts setting high targets of up to $7.50.
The company has received positive FDA feedback, clearing the path for an IND in breast cancer trials, and phase 2 I-SPY data is strong.
The CEO has shown confidence in the stock by buying shares, and the company's higher float status may contribute to its momentum.

Generated by AI

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will participate as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), being held October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston, MA.

6d agoYahoo Finance

Atossa Updates Pipeline and Strategy in Corporate Presentation

Tipranks Press Release.

11d agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX)

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026.

1mo agoYahoo Finance

Atossa study shows preclinical activity in breast cancer models

2mo agoInvesting.com

Also Discussed

Investors talking about ATOS also mention

#	Name	Attention
1	InspireMD, Inc.NSPR	0%new
2	Jaguar Health, Inc.JAGX	0.02%-0.02
3	AEZS - Aeterna Zentaris Inc.	——
4	Bionano Genomics Inc.BNGO	0%0
5	Bio-Path Holdings Inc.BPTH	0%0
6	Citius Pharmaceuticals, Inc.CTXR	0%new
7	GENE - Genetic Technologies Limited	——
8	ABIO - ARCA biopharma, Inc.	——
9	Castor Maritime Inc.CTRM	0%new
10	AVGR - Avinger, Inc.	——

Atossa Genetics Inc

Healthcare
Biotechnology

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast health conditions. The company’s work centers on oncology, with an emphasis on hormone-driven disease areas and related unmet medical needs. Its current pipeline includes investigational medicines and therapeutic programs designed to address breast cancer prevention and treatment, as well as selected rare diseases where estrogen-related biology may be relevant. Atossa Therapeutics also advances diagnostic capabilities connected to breast health, supporting a broader approach to disease management. Based in Seattle, Washington, the company operates within the biotechnology sector and plays a role in translating research into potential treatment options for women’s health and cancer care.

Website

Location

448 NW Market Street

Seattle, WA, 98107

United States

Social

What share of all stock conversation is about ATOS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

Aug 17

Atossa Therapeutics, Inc. ($ATOS) has a market capitalization of $25M, which is significantly lower than its peers, potentially leading to a 38x increase in value.
The company is expected to release trial data by the end of August or early September, which could be a catalyst for the stock to rise.
There are concerns that Atossa may struggle to fund its phase 2 study without a significant injection of capital, which could lead to a reverse split or delisting.

Generated by AI

Sentiment

Of the messages about ATOS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% new	12.5% -87.5	70.37% +2.19	67.13% -4.66
Bearish	50% -50	87.5% new	29.63% -2.19	32.87% +4.66

Bullish· Feb 3

The stock has been beaten down significantly, offering a potential buying opportunity with a possible recovery.
The company's product has been undervalued, and a shift in management's attitude could lead to increased confidence and a boost in the stock price.
The stock is showing signs of a potential bottom, with a possible breakout and increased momentum following a recent surge in volume.

Bearish· Jun 24

The company's management has diluted stock to pay themselves, causing losses for shareholders.
The company is still in the early stages of development and lacks meaningful data, making it unlikely to receive FDA approval soon.
The company's reverse split may lead to delisting from the NYSE due to a rule against multiple splits within a year, and a move to the OTC market could be disastrous for shareholders.

Generated by AI

Topics

Of the messages about ATOS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	56.67%	29.3%
Analysts	—	—	0%	27.69%
Technical Analysis	—	—	0%	33.49%
Controversies	—	—	43.33%	2.44%
Earnings	—	—	0%	0.41%
Macro	—	—	0%	6.66%

Announcements· Jul 29

Atossa Therapeutics ($ATOS) received positive written feedback from the FDA regarding its proposed dose optimization trial of (Z)-endoxifen for ER+/HER2- metastatic breast cancer.
The FDA affirmed key elements of the company's clinical development plan, including the dose-optimization strategy, nonclinical data, combination therapy approach, and cardiac safety, without requiring a pre-IND meeting.
Atossa Therapeutics is advancing toward IND submission for its (Z)-Endoxifen clinical program in ER+/HER2- metastatic breast cancer, with a target submission date in Q4 2025.

Controversies· Feb 15

ATOS is mentioned in a post that criticizes the FDA, potentially implying a negative impact on the company.
The post implies that the FDA's actions or decisions may be seen as unpredictable or incompetent.
The tone of the post is negative and sarcastic, potentially affecting investor sentiment.

Technical Analysis· Dec 11

The author sees up to 50% upside potential for $ATOS, with a first wall at $0.95 and a bullish momentum as long as it remains above $0.80.
Technical levels of interest for $ATOS include $1.05, $2.31, and $0.90, with potential resistance at $1.05 and a recent high/squeeze zone at $2.31.
The author notes that $ATOS has been in an uptrend since December 1, with a bottom at $0.70, and suggests setting limit buys in the mid-to-late $0.80 range for swing trades.

Generated by AI

Community

Of the messages about ATOS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	88.71%	87.86%
Newcomers	0%	0%	11.29%	12.14%

Regulars· Aug 17

The potential catalysts for the stock's price increase include the Evangeline trial data by the end of August or early September, followed by the I-SPY2 data and Karisma durability data by the end of September.
The stock's market capitalization is still under $26 million, which is considered relatively low compared to similar biotech companies in phase 3 with less drug candidates, potentially leading to a significant price increase.
The company's prospects for FDA approval and continued funding are uncertain, with some users expressing skepticism about the stock's potential for significant growth, while others are optimistic about the company's prospects despite the lack of news.

Newcomers· Jul 29

$ATOS stock has seen a 22% increase premarket, with analysts setting high targets of up to $7.50.
The company has received positive FDA feedback, clearing the path for an IND in breast cancer trials, and phase 2 I-SPY data is strong.
The CEO has shown confidence in the stock by buying shares, and the company's higher float status may contribute to its momentum.

Generated by AI

Atossa Genetics

Social

Aug 17

Bullish· Feb 3

Bearish· Jun 24

Announcements· Jul 29

Controversies· Feb 15

Technical Analysis· Dec 11

Regulars· Aug 17

Newcomers· Jul 29

Atossa plans CVR issuance tied to priority review voucher

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Atossa Updates Pipeline and Strategy in Corporate Presentation

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX)

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa study shows preclinical activity in breast cancer models

Also Discussed

Atossa Genetics Inc

Company Information

Location

Atossa plans CVR issuance tied to priority review voucher

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Atossa Updates Pipeline and Strategy in Corporate Presentation

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX)

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa study shows preclinical activity in breast cancer models

Also Discussed

Social

Aug 17

Bullish· Feb 3

Bearish· Jun 24

Announcements· Jul 29

Controversies· Feb 15

Technical Analysis· Dec 11

Regulars· Aug 17

Newcomers· Jul 29